Grants and Contributions:
Title:
Validation of a unique High Precision Cold Plasma Device as adjuvant for breast cancer radiotherapy Phase 2
Agreement Number:
935250
Agreement Value:
$119,200.00
Agreement Date:
Sep 2, 2019 - Mar 31, 2021
Description:
This project enhances the development of a unique high precision cold plasma device as a adjuvant for breast cancer radiotherapy. More particularly, the detailed design, fabrication and commissioning of this prototype will be performed so that it can be used in clinical trials in Canada.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Montreal, Quebec, CA H4A 2T7
Reference Number:
172-2019-2020-Q3-935250
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
819165614
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The total amended value is 26,000 dollars.
Amendment Date
Feb 17, 2021
Recipient's Legal Name:
NexPlasmaGen Incorporée
Federal Riding Name:
Notre-Dame-de-Grâce--Westmount
Federal Riding Number:
24053
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
339110
Amendments: